GLP-1 Drugs and Sleep Apnea — A Breakthrough? - Who Gets Left Behind?

Julia Cartwright examines who gets left behind as tirzepatide becomes the first FDA-approved drug for sleep apnea with obesity. We discuss cost barriers, insurance gaps, and equity concerns surrounding this breakthrough treatment, covering real-world access challenges that prevent many patients from benefiting despite promising trial results. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.